Academic Journal
Bottom up design of nanoparticles for anti-cancer diapeutics:'put the drug in the cancer's food'
| العنوان: | Bottom up design of nanoparticles for anti-cancer diapeutics:'put the drug in the cancer's food' |
|---|---|
| المؤلفون: | Needham, David, Arslanagic, Amina, Glud, Kasper, Hervella, Pablo, Karimi, Leena, Høilund-Carlsen, Poul Flemming, Kinoshita, Koji, Mollenhauer, Jan, Ortiz, Elisa Parra, Madsen, Anders Utoft, Walke, Prasad |
| المصدر: | Needham , D , Arslanagic , A , Glud , K , Hervella , P , Karimi , L , Høilund-Carlsen , P F , Kinoshita , K , Mollenhauer , J , Ortiz , E P , Madsen , A U & Walke , P 2016 , ' Bottom up design of nanoparticles for anti-cancer diapeutics : "put the drug in the cancer's food" ' , Journal of Drug Targeting , vol. 24 , no. 9 , pp. 836-856 . https://doi.org/10.1080/1061186X.2016.1238092 |
| سنة النشر: | 2016 |
| المجموعة: | University of Southern Denmark: Research Output / Syddansk Universitet |
| الوصف: | The story starts in Basel at CLINAM in 2013, when I asked Pieter about making nanoparticles and he advised me to "try this solvent-exchange method we have developed for making limit sized particles". We are particularly interested in what are "limit size materials" because we want to test the feasibility of an idea: could we design, make, develop, and test the concept for treating metastatic cancer by, "Putting the Drug in the Cancer's Food? "Limit size" is the size of the cancer's food, ? the common Low Density Lipoprotein, (LDL) ~20 nm diameter. In this contribution to Pieter's LTAA we focus on the "bottom" (nucleation) and the "up" (growth) of "bottom-up design" as it applies to homogeneous nucleation of especially, hydrophobic drugs and the 8 physico-chemical stages and associated parameters that determine the initial size, and any subsequent coarsening, of a nanoparticle suspension. We show that, when made by the rapid solvent-exchange method, the same sized particles can be obtained without phospholipid. Furthermore, the obtained size follows the predictions of classic nucleation theory when the appropriate values for the parameters (surface tension and supersaturation) at nucleation are included. Calculations on dissolution time for nanoparticles reveal that a typical fewmicromolar-solubility, hydrophobic, anti-cancer drug (like Lapatinib, Niclosamide, Abiraterone, and Fulvestrant) of 500 nm diameter would take between 3?7 s to dissolve in an infinite sink like the blood stream; and a 50 nm particle would dissolve in less than a second! And so the nanoparticle design requires a highly water-insoluble drug, and a tight, encapsulating, impermeable lipid:cholesterol monolayer. While the "Y" junction can be used to mix an ethanolic solution with anti-solvent, we find that a "no-junction" can give equally good results. A series of nanoparticles (DiI-fluorescently labeled Triolein-cored and drug-cored nanoparticles of Orlistat) were then tested in well-characterized cell lines for uptake and efficacy as well as ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://portal.findresearcher.sdu.dk/da/publications/751561f4-8bf3-42a1-aea9-082c7384b657 |
| DOI: | 10.1080/1061186X.2016.1238092 |
| الاتاحة: | https://portal.findresearcher.sdu.dk/da/publications/751561f4-8bf3-42a1-aea9-082c7384b657 https://doi.org/10.1080/1061186X.2016.1238092 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.1AD72F5C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1080/1061186X.2016.1238092 |
|---|